Envision Healthcare Holdings Inc. Acquisition May Not Be in the Best Interests of EVHC Shareholders
NEW YORK, June 20, 2016 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Envision Healthcare Holdings Inc. ("EVHC" or the "Company") in connection with the Company's proposed plan of merger with AmSurg Corp. ("AmSurg"), announced on June 15, 2016. Under the terms of the agreement, EVHC shareholders will receive 0.334 of a share of AmSurg common stock for each EVHC share they own, representing consideration of $25.89 per share.
WeissLaw is investigating whether EVHC's Board acted to maximize shareholder value prior to entering into the agreement. Notably, at least one analyst set a target price of $37.00 per share, or $11.11 above the offer price. Additionally, the offer price is also $20.06 below the Company's 52-week high of $45.95. Finally, on June 14, the day before the announcement, EVHC shares traded at $27.76, or $1.87 above the offer price.
Given these facts, WeissLaw is investigating the Board of Directors' decision to sell EVHC and whether EVHC shareholders will obtain their fair proportionate share of the Company's continued success and future growth prospects. If you own EVHC shares and would like more information about your rights or our investigation, please contact Joshua Rubin either by telephone at (888) 593-4771 or by email at [email protected].
WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected] or fill out the form on our website, http://www.weisslawllp.com/contact/report_fraud/.
SOURCE WeissLaw LLP
Share this article